KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

被引：74

作者：

Brahmer, J. R. ^{[1
]}

Rodriguez-Abreu, D. ^{[2
]}

Robinson, A. G. ^{[3
,4
]}

Hui, R. ^{[3
,4
]}

Csoszi, T. ^{[5
]}

Fulop, A. ^{[6
]}

Gottfried, M. ^{[7
]}

Peled, N. ^{[8
]}

Tafreshi, A. ^{[9
,10
]}

Cuffe, S. ^{[11
,12
]}

O'Brien, M. ^{[13
]}

Rao, S. ^{[14
]}

Hotta, K. ^{[15
]}

Leal, T. A. ^{[16
]}

Riess, J. W. ^{[17
]}

Jensen, E. ^{[18
]}

Zhao, B. ^{[18
]}

Pietanza, M. C. ^{[18
]}

Reck, M. ^{[19
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA

[2] Hosp Univ Insular Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain

[3] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[4] Univ Sydney, Sydney, NSW, Australia

[5] Jasz Nagykun Szolnok Cty Hosp, Oncol, Szolnok, Hungary

[6] Orszagos Koranyi Pulmonol Intezet, Med Oncol, Budapest, Hungary

[7] Meir Med Ctr, Med Oncol, Kefar Sava, Israel

[8] Soroka Univ Med Ctr, Ctr Canc, Beer Sheva, Israel

[9] Wollongong Private Hosp, Med Oncol, Wollongong, NSW, Australia

[10] Univ Wollongong, Wollongong, NSW, Australia

[11] St James Hosp, Med Oncol, Dublin, Ireland

[12] Canc Trials Ireland, Dublin, Ireland

[13] Royal Marsden Hosp, Med Oncol, Sutton, Surrey, England

[14] MedStar Franklin Sq Hosp, Med Oncol, Baltimore, MD USA

[15] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[16] Univ Wisconsin, Carbone Canc Ctr, Div Hematol & Oncol, Madison, WI USA

[17] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA

[18] Merck & Co Inc, Oncol, Kenilworth, NJ USA

[19] German Ctr Lung Res, Airway Res Ctr North, Lungen Clin, Grosshansdorf, Germany

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA51

引用

页码：S1181 / S1182

页数：2

共 50 条

[1] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Reck, M.
Rodr-Guez-Abreu, D.
Robinson, A. G.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M.
Rao, S.
Hotta, K.
Leiby, M.
Lubiniecki, G. M.
Shentu, Y.
Rangwala, R.
Brahmer, J. R.
ANNALS OF ONCOLOGY, 2016, 27
[2] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Reck, M.
Rodriguez-Abreu, D.
Robinson, A.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M. E.
Rao, S.
Hotta, K.
Leiby, M.
Lubiniecki, G.
Shentu, Y.
Rangwala, R.
Brahmer, J.
ANNALS OF ONCOLOGY, 2016, 27
[3] KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%
Brahmer, J.
Rodriguez-Abreu, D.
Robinson, A.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M.
Rao, S.
Hotta, K.
Riccio, A.
Yang, J.
Pietanza, M. C.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S153 - S153
[4] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%
Brahmer, J.
Rodriguez-Abreu, D.
Robinson, A.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M.
Rao, S.
Hotta, K.
Riccio, A.
Yang, J.
Pietanza, M. C.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1793 - S1794
[5] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
Lopes, Gilberto
Wu, Yi-Long
Kudaba, Iveta
Kowalski, Dariusz
Cho, Byoung Chul
Castro, Gilberto
Srimuninnimit, Vichien
Bondarenko, Igor
Kubota, Kaoru
Lubiniecki, Gregory M.
Zhang, Jin
Kush, Debra A.
Mok, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[6] Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Wu, Y-L.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Souza, F.
Lin, J.
Wang, J.
Li, B.
Mok, T.
ANNALS OF ONCOLOGY, 2020, 31 : S1394 - S1394
[7] Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
Boyer, M.
Mclean, J.
Xu, L.
Samkari, A.
Carbone, D.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
[8] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
Lopes, G.
Wu, Y.
Kudaba, I.
Kowalski, D.
Cho, B.
Turna, H.
De Castro, G., Jr.
Srimuninnimit, V.
Laktionov, K.
Bondarenko, I.
Kubota, K.
Lubiniecki, G.
Zhang, J.
Kush, D.
Mok, T.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
[9] Progression after the Next Line of Therapy (PFS2) and Updated OS Among Patients with Advanced NSCLC and PD-L1 tumour Proportion Score (TPS) ≥50% Enrolled in KEYNOTE-024
Brahmer, Julie R.
Rodriguez-Abreu, Delvys
Robinson, Andrew G.
Hui, Rina
Csoszi, Tibor
Fulop, Andrea
Gottfried, Maya
Peled, Nir
Tafreshi, Ali
Cuffe, Sinead
O'Brien, Mary
Rao, Suman
Hotta, Katsuyuki
Leiby, Melanie A.
McLean, Jessica
Shentu, Yue
Rangwala, Reshma
Reck, Martin
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 75 - 76
[10] Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024
Brahmer, Julie R.
Rodriguez-Abreu, Delvys
Robinson, Andrew G.
Hui, Rina
Csoszi, Tibor
Fulop, Andrea
Gottfried, Maya
Peled, Nir
Tafreshi, Ali
Cuffe, Sinead
O'Brien, Mary
Rao, Suman
Hotta, Katsuyuki
Deitz, Anne C.
Lubiniecki, Gregory M.
Zhang, Jin
Rangwala, Reshma
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S8 - S9

← 1 2 3 4 5 →